english.prescrire.org > Spotlight > Archives : 2024 > Bupropion + naltrexone (Mysimba°) for weight loss: set to be withdrawn from the market in the European Union?

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2024 : 1 | 30 | 60

Bupropion + naltrexone (Mysimba°) for weight loss: set to be withdrawn from the market in the European Union?

 Marketing Authorisations   The pharmaceutical company Orexigen Therapeutics has failed to fulfil its obligation to conduct a post-authorisation trial to assess the long-term cardiovascular adverse effects of the fixed-dose combination of bupropion + naltrexone (Mysimba°), which is authorised in the European Union for use in patients with obesity or who are overweight. Now, 9 years after its authorisation, the European Commission has asked the European Medicines Agency to review its harm-benefit balance.
Full article available for download by subscribers

©Prescrire 1 September 2024

Source: "Bupropion + naltrexone (Mysimba°) for weight loss: set to be withdrawn from the market in the European Union?" Prescrire Int 2024; 33 (262): 212. Subscribers only.

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook Share on Twitter
 
See also:

"Naltrexone + bupropion.
Too risky for only modest
weight loss"
Prescrire Int 2015;
24 (164): 229-233.
Subscribers only

"Towards better patient care:
drugs to avoid in 2024
(Diabetes – Nutrition)"
Prescrire Int 2024;